The phase II KEYNOTE-199 study included three cohorts of patients with mCRPC treated with docetaxel and one or more targeted endocrine therapies. Cohorts 1 and 2 enrolled patients with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback